Richard W. Klauer Joins Valencia Technologies as VP of Sales
In an exciting development, Valencia Technologies has appointed Richard W. Klauer as the new Vice President of Sales. Valencia Technologies specializes in neuromodulation and is dedicated to transforming the treatment of urgency urinary incontinence. With a robust background in medical device sales, Rich Klauer is set to lead the company’s commercial team as they expand their impact in the healthcare market.
Richard Klauer's Experience and Expertise
Rich brings over twenty years of invaluable experience in the medical device industry, particularly in urology. His extensive knowledge encompasses various sub-specialties within urology, particularly focusing on both men's and women’s health issues. Throughout his career, he has demonstrated remarkable success in building and directing sales teams, leading them to achieve significant growth through innovative medical technologies.
Contributions to the Medical Device Industry
Klauer has a proven track record of success, having played a crucial role in expanding early-stage medical organizations. His capacity to build strategic partnerships and navigate complex market challenges has allowed him to consistently drive success in all the companies he has worked with. His transition to Valencia Technologies marks a significant stride towards enhancing the commercial aspects of the eCoin system.
Focusing on the eCoin System
In his new role at Valencia Technologies, Klauer will prioritize the commercial adoption of the eCoin system. This advanced device offers a minimally invasive solution for treating urgency urinary incontinence, a condition affecting many individuals across the country. Klauer expressed his enthusiasm about joining an innovative company like Valencia Technologies, highlighting his eagerness to expand access to the eCoin for patients and practitioners alike.
Understanding the eCoin Device
The eCoin device is a groundbreaking neurostimulator, about the size of a coin, that is implanted under the skin near the ankle. The procedure is minimally invasive and outpatient, using local anesthetic for patient comfort. Once implanted, the device provides regular stimulation to the tibial nerve twice a week. This innovative approach has reportedly reduced episodes of urgency urinary incontinence by at least 50% in 75% of patients within a year of use.
Valencia Technologies: Pioneering Solutions in Healthcare
Valencia Technologies develops the eCoin system, which is recognized as the first and only FDA-approved, subcutaneous implantable tibial nerve stimulator specifically for treating UUI. The company's vision is to make the eCoin procedure widely accessible, aiming for most surgeries to occur within physicians' clinics. The FDA approval received for the eCoin system in 2022 highlights its reliability and effectiveness, positioning Valencia Technologies as a leader in this crucial medical field.
Commitment to Patient Care
As Valencia Technologies moves forward under the leadership of Richard Klauer, there is a renewed commitment to enhancing patient care and outcomes in the urology landscape. The focus on the eCoin system represents not only a technological advancement but also a dedicated effort to address a common issue faced by many individuals.
Frequently Asked Questions
Who is Richard W. Klauer?
Richard W. Klauer is the newly appointed Vice President of Sales at Valencia Technologies, bringing over twenty years of experience in medical device sales.
What is the eCoin system?
The eCoin system is a subcutaneous implantable tibial nerve stimulator designed to treat urgency urinary incontinence.
What is Valencia Technologies' vision?
Valencia Technologies aims to make the eCoin implant procedure readily accessible in physicians' clinics.
How effective is the eCoin device?
Clinical studies show that the eCoin system reduced episodes of urgency urinary incontinence by at least 50% in 75% of patients at one year.
When did Valencia Technologies receive FDA approval for the eCoin system?
Valencia Technologies obtained FDA approval for the eCoin system in 2022, marking a significant milestone in treatment options for patients.
